Progenics' first commercial product, RELISTOR ® (methylnaltrexone bromide) for OIC, is partnered with Valeant Pharmaceuticals International, Inc. This press release may contain projections and other "forward-looking statements" regarding future events. Statements contained in this communication that refer to Progenics' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Progenics' current perspective of existing trends and information as of the date of this communication.